Month: September 2011

Only 7% of women who suffers collapse or weakening of hair visit to the dermatologist.

|

Only 7% of women who suffers collapse or weakening of hair visit to the dermatologist.

-46 per cent of those surveyed use cosmetics and food supplements to fight against the loss or weakening of hair

-23.9 Per cent believed that the Barber is a reference to get advice on hair loss

-20% of women relies on the media to report about your problem

Madrid, 2011-September Viviscal, brand recognized worldwide as hair regeneration system, has released the results of its survey on the loss of hair. According to this survey of 1000 Spanish women between the ages of 20 and 60 years, 7% of Spanish women has suffered loss or weakening of hair at some point in their life attends the dermatologist.

To the question about what they have tried to resolve the loss or the fall stresses 46.25 per cent seeks the solution in the vitamin supplements and cosmetics to 37.7% of those surveyed consulted professionals. Within this 37.7%, the majority response indicates that he has asked Council at the pharmacy with a 11 per cent, followed by 8 per cent consulted with a doctor and a 7% which has come to a specialist in dermatology.

As to who or where expect advice on this problem, first of all, a 32.8% is of the view that doctors are best suited to give advice. Then they point out the Hall of hairdresser with a 23.9%, followed by the media with a 19.9%. 13.3% Was the Pharmacy and a 10.2% to the herbal.

To Eugenia Vázquez, Marketing Director, Viviscal, Spain, “ although most regard doctors as the most appropriate figure to give advice, if compared to the previous question, it is shocking to see how only 7% of those surveyed expressed having gone to the dermatologist to remedy your problem. It is something that surprised us ”.

The survey highlights that magazines and TV shows are the most followed media. Specifically, 25% seeks advice on television about health and beauty programmes, matched with 25% who advises with health magazines. It is remarkable that 23% search tools to solve this problem in women’s magazines, followed by 14% which makes it over the Internet, 7% reporting in radio and 6 per cent which seeks the solution in the newspapers.

Survey data

Stressed communication has done at the request of Viviscal a quantitative survey among Spanish women to know their level of concern about the loss of hair, as well as the solutions that have been taken to solve this problem.

The target audience for this action has been Spanish women from 2 to 60 years of age living in the rural and urban area.

This target according to the population Spanish age according to INE 2004 (last published) account for 11.665.174 women.

Therefore, for this universe and looking for a confidence level of 95% for p and q = 50, if we want to get results with an error sample of 3.1% is necessary to carry out a total of 1000 surveys.

Annex

Universe: total number of potential respondents.

Confidence level: indicates the likelihood that the results of our research are true. 95% Confidence indicates a probability of error of 5%

and Q: P is the proportion of individuals who possess characteristic of the study (concern for the fall of the hair) in the population Q collects the proportion of individuals who do not have this feature. Both values are usually strangers are always weighted at 50%.

Sampling error: is the difference which may be between the result we get asking a sample of the population and that would get if we were to the total.

About Viviscal

Produced in Finland and commercialized in about 25 countries, Viviscal is one of the brands of leading natural supplements on the market worldwide, thanks to their effectiveness tested with five clinical studies published in recognized daily doctors in Europe and Latin America.

In 100% of participants in clinical trials, the fall of hair was stopped after two months and 85% regenerated in a total way after eight months. The active ingredient of Viviscal is a rich protein composed of marine extracts, called AminoMar C ™ together with vitamin C and silica.

Read More

InterSystems acquires Siemens Health Services in France and stands as a sector leader.

|

InterSystems acquires Siemens Health Services in France and is positioned as leading sectoral.

Madrid, 2011-September InterSystems Corporation announces strategic acquisition of Siemens Health Services France (SHS) to its parent company Siemens. SHS, traditional leader in the provision of health solutions to French hospitals, will operate from now on as “ InterSystems SAS ”. This purchase puts InterSystems in a leadership position in France, which is one of five global markets it to health most important in billing. The acquisition, in addition, marks the entrance of the advanced clinical applications InterSystems TrakCare ™ in this market.

Paul Grabscheid, Vice President for Strategic Planning of InterSystems asserts that “ SHS is very respected by its system administration and invoicing Clinicom ™ for hospitals, which is used by more than 60 institutions, including some of the more advanced users of the health area of the country. This initiative offers France the global experience in health software InterSystems TrakCare, which complements and extends the capabilities of Clinicom ”.

TrakCare is used by leading institutions in 25 countries, with deployments ranging from small hospitals to regional networks of assistance, fully integrated with the networks serving millions of patients. In France, Clinicom and TrakCare will be combined to set up a complete clinical and administrative system optimized for policies and French sanitary practices. This combination is facilitated by both products run on the technology of InterSystems cache ® database and the two organizations have been working as partner since more than one decade ago.

“ This acquisition significantly expands the options available to customers ”, continuous Grabscheid. “ they will have the benefits of the investment made in Clinicom, which follow us by strengthening and supporting, and will have advanced clinical capabilities of TrakCare to reinforce the safety and efficacy of the services that give their patients; finally, you can use technology to the networked InterSystems HealthShare health ™ to link systems and people in your organization, your community or your region ”.

InterSystems SAS will focus on the public sector hospitals, which account for 62% of the French hospital market. The business private health of SHS has been sold to WEB100T which, with headquarters in Merignac (France) has a wide and solid experience in this sector. It is expected that sales to Web100T process is completed in a few months, once the necessary legal process has been completed.

InterSystems is a global leader in advanced solutions for the networked health, with major projects for the clinic electronic history (HCE) ongoing and in various countries, such as cases of Sweden, United Kingdom (Scotland and England) Chile, Brazil and United States.

About InterSystems

InterSystems Corporation is the world leader in innovative solutions for the networked health. Headquartered in Cambridge, Massachusetts, and offices in 23 countries, InterSystems provides advanced technology to cutting-edge applications.

InterSystems Ensemble ® is a seamless integration and hot-pluggable application development platform. InterSystems cache ® is a database, high performance objects, that allows applications to be faster and more scalable. InterSystems HealthShare ™ is a strategic platform for Health Informatics and the creation of the electronic medical history at regional and national levels. InterSystems DeepSee ™ is a software that makes it possible to embed real-time Business Intelligence capabilities in transactional applications.

InterSystems is the No. 1 of databases and applications for health integration technologies. InterSystems products are used in thousands of hospitals and laboratories worldwide, including 17 hospitals Honor Roll of America ’ s Best Hospitals, according to the classification of U.S. News & World Report.

Cache can be requested or download through the InterSystems website, where a free, fully functional version is available and unlimited duration.

Read More

The Journal of medicine publishes study CS21A with new data showing the long term benefits of degarelix for hormonodependiente prostate cancer.

|

The Journal of medicine publishes study CS21A with new data showing the long-term benefits of degarelix for prostate cancer hormonodependiente.

Suppression rapid and sustained testosterone and an improvement in the control of the PSA can be delayed therapy of second line

Saint-Prex, Switzerland, 2011-September The number of September in The Journal of medicine publishes results of the study CS21A with new data showing that degarelix, an antagonist of the hormone gonadotropin (GnRH) approved for the treatment of prostate cancer advanced both the EU and USA, continues to be effective and well tolerated after three years of treatment. This new study extends the findings of the study phase III registration (CS21), in which the risk of progression of PSA or death was significantly lower in those patients who received degarelix compared with those who received leuprorelina (an LHRH agonist) up to one (1) year. This extension study demonstrated that patients who continued treatment, the removal of PSA and the impact on PSA progression-free survival remained constant (42 months) (1) long term.

In addition, in the study were investigated patients changed from leuprorelina to degarelix after one year of treatment. With a median of 27.5-month follow-up data showed decreased risk in PSA progression-free survival (p = 0, 003) (1).

It is important to delay time to progression of the PSA as it indicates the time until that prostate cancer becomes hormonoresistente. You can also delay the onset of a second line treatment, which includes chemotherapy (2). The time until the hormone-resistance is also an important indicator of survival (3). These findings support the use of degarelix as first-line (1) androgen deprivation therapy.

CS21A was designed with the aim of collecting more data on the safety and tolerability of degarelix. After the end of the phase III trial offered to all patients the option of receiving degarelix as part of the extension study. All patients who had received such therapy continued with their treatment and be realeatorizó to those who had been previously treated with leuprorelina to receive degarelix.

“to delay the maximum time possible hormonal-resistance is an important result for any first-line therapy,” says e. David Crawford, MD, Chief of the section of Oncology and Professor of Urologic Oncology and Oncology of the University of DenverColorado, United States. UU. «data from the phase III extension study show that degarelix provides patients with prostate cancer effective control of testosterone and PSA in the long term, which in turn may delay the androgen resistance.»

Prostate cancer is the second leading cause of death from cancer in men in the Western world (4). Up to 40% of men who are diagnosed with prostate cancer will develop advanced disease, and although most respond to initial surgical or medical castration, the progression is inevitable until (CPHR) hormone-resistant prostate cancer (5). Half of the patients with CPHR survival is two to three years (5).

Degarelix works by inhibiting immediately GnRH receptors in the pituitary gland by suppressing the luteinizing hormone, which reduces the production of testosterone from testes without causing the initial flare. Prostate cancer depends on testosterone for growth, so the goal of therapy is to quickly reduce testosterone levels to slow the growth of cancer cells. To avoid the initial flare of testosterone prevents the initial exacerbation of clinical status, allowing a more rapid relief of symptoms such as bone pain, urethral obstruction and spinal cord compression, in addition to eliminating the need to manage a concomitant treatment with antiandrogens (6,7,8).

The study of CS21A

The study of extension of the trial of degarelix against leuprorelina (CS21) registration is designed with the aim of gathering more data on their safety and tolerability. After the end of the phase III trial offered to all patients the option of receiving degarelix as part of the extension study. All patients who had received continued with their treatment and be realeatorizó to those who had been previously treated with leuprorelina to receive degarelix 240/80 mg or 240/160 mg.

The primary criterion of assessment was the safety and tolerability and side valuation criteria were the response of testosterone, PSA, luteinizing hormone and follicle stimulating hormone, as well as the progression of PSA and of progression-free survival

CS21A was launched in March 2007 and analysis was performed in March 2010 with a median follow-up of 27.5 months. CS21A continues and will have a duration of five years.

Degarelix

It has unique chemical characteristics and a new mechanism of action, different from conventional hormone therapies. Degarelix is administered as a subcutaneous injection and rapidly reduces the levels of PSA in two weeks immediately blocking GnRH receptors in the pituitary gland. By blocking the receptors suppresses the release of luteinizing hormone and follicle stimulating hormone, so that reduces the production of testosterone in the testes to castration levels at three days. Prostate cancer depends on testosterone for growth and to reduce testosterone levels slows the growth of cancer cells.

In clinical studies, degarelix suppressed testosterone and PSA faster than the leuprorelina, a treatment is already available for advanced prostate cancer (9).

In clinical trials, it was well tolerated in general. The most common side effects were hot flashes, pain and Erythema at the point of injection, weight gain, nasofaringitis, fatigue and pain of back (9.10).

Prostate cancer

Prostate cancer is the most common form of male cancer in the Western world (11) and the second leading cause of death from cancer in men in some countries (4). Each year are diagnosed in Europe about 300,000 new cases of prostate cancer. Globally this figure rises to 670,000 (12) cases. For more information and the latest news about prostate cancer, visit the web site of information on Ferring.

Ferring

Ferring is a biopharmaceutical specialist based in Switzerland that focuses on research and has presence in global markets. The company identifies, develops and commercializes innovative products in the areas of reproductive health, urology, Gastroenterology and endocrinology. In recent years, Ferring has expanded beyond its traditional European base and carries out operations in more than 50 countries.

Bibliography

(1) Crawford, ED et to the. The Journal of medicine September 2011; 186 (3): 889-897

(2) Mahon KL, et to the. Endocr Relat Cancer 2011; 18:R103 – R123

(3) Bournakis E, et to the. Icancer Res 2011: Apr; 31 (4): 1475-82

(4) American Cancer Society. Available here.

(5) Beltran, H et to the. European medicine 60 (2011) 279 – 290

(6) Van Poppel, H et to the. Medicine: June 2009; Volume 71, Issue 6: 1001-1006

(7) B-E Persson, et to the. Neuroendocrinology 2009; 90: 235 – 244

(8) L Boccon-Gibod, et to the. Therap Advisor Ural June 2011

(9) Klotz L, et to the. BJU int. 2008; 102 (11): 1531-1538.

(10) Van Poppel H et to the. Abstract (23) Euro Ural Suppl. 2007; 6 (2): 28

(11) University of Iowa Hospitals and Clinics. available here.

(12) Cancer Research UK. Available here

Read More

The MICINN encourages private investment in venture capital in the bio sectors and industrial technologies in INNVIERTE sustainable economy programme.

|

The MICINN encourages private investment in venture capital in the bio sectors and industrial technologies within the programme INNVIERTE economy sustainable.

with the goal of providing financing to innovative with equity private. companies

-The Ministry of science and innovation, through the CDTI, has begun within the framework of the sustainable economy INNVIERTE programme, two public procedures in the bio and sectors of industrial technologies, selection of private investment initiatives that form part of investors projects public-private venture capital

-the goal is for companies participating in private initiatives finally chosen to exercise companies tractors of those small and medium-sized technology companies that develop their activity in the environment in these sectors, are owned by finally constituted investment vehicles

-private investment initiatives that attend both selection procedures shall be formed by leading companies in the bio and fields of industrial technologies

Spaina, 2011-September the Ministry of science and innovation, through the Centre for Industrial technological development (CDTI), has launched the selection process to choose private investment initiatives involving investors projects private venture capital in the bio sectors and industrial technologies.

Both selection procedures are part of the sustainable economy INNVIERTE programme to the Ministry of science and innovation, through the CDTI, being implemented with the aim of fostering, through public-private venture capital, development and consolidation of innovative technology-based companies and high potential for economic growth.

Sector bio

The selection process of private initiatives of industrial capital in the bio sector considers both companies operating in the pharmaceutical sector in the sectors of biotechnology for human health and the health technology (products, equipment and software for medical use), all of them high-tech and knowledge-intensive. These sectors are characterized by their high productivity and growing presence in international markets. In fact, companies that are framed in the same are leaders featured in investment in industrial r & d in Spain, which generates important positive effects on the whole of the economy.

Industrial technologies

Similarly, in the field of industrial technologies CDTI provides for sectors of activity aimed at generating industrial sector to develop innovative products and processes. These sectors, which are characterized by being very globalized, technology and innovation, key tools needed to continue competing.

As a result of both selection procedures, the CDTI shall elect one or several initiatives of private investment in each of the areas to which they are confined. The aim is that companies tractors that participate in this initiative enhance the activity of investments – small and medium-sized technology companies in this sector – which will provide not only funding, but also capacity management, internationalization and market knowledge.

INNVIERTE sustainable economy programme is part of the State strategy of innovation (e2i). Specifically, INNVIERTE sustainable economy is one of the preferred shares of the first of the five pillars of the e2i, which integrates all actions designed to achieve an environment of financing that encourages and facilitates innovative activity.

The deadline for submitting proposals ends October 7 investment initiatives private who attend this selection procedure may be formed by a single leader or a set of leading companies in the sector in which there are. Thus ensures that participants provide knowledge of the business, market and technology, as well as access to new customers and opportunities of globalization. In order to demonstrate these capabilities, each initiative participants shall justify high market share and leadership in the sector at the national level, high percentage of investment in r & d activities with respect to its turnover and large international presence.

Private capital there in every private investment initiative (n) committed the (s) Enterprise (s) leader (s) that integrate must be equal to or more than 12 million euros.

In both cases, the deadline for submitting proposals is open from September 1 until October 7, 2011.

Read More

They released the second edition of the “Mediosysida” award for young journalists.

|

Launches the second edition of the award “ Mediosysida ” for young journalists.

30 years of HIV communication media

Spain, 2011-September The community network on HIV/AIDS in the State Spanish (REDVIH) announces the “ II Mediosysida Award for young journalists ”, in order to recognize and promote professional practices of the journalists under the age of 35 whose work will contribute to improving the social image of HIV in the media in Spain.

The launch of the second edition of the award coincides with the publication of the first journalistic note on HIV for 30 years, on June 5, 1981. The article appeared in the American newspaper Los Angeles Times, under the headline: “ are studied cases of pneumonia in gay men ”. Three decades have passed since then and the media have experienced an evolution in the treatment of information about HIV. The lack of information from the start of the pandemic has given way to a more rigorous information but still dragging on some occasions, prejudices, stigma and discrimination or simplification that day marked the information about HIV.

“ Realizing that even today still detecting incorrect terminology, prejudices and discrimination towards people living with HIV in some newspaper reports, the Mediosysida project is working to change the social image of HIV along with journalists and NGOs with the aim of improving the quality of life of persons ”, says Maria UrreroCoordinator of the project, which adds that “ with the award for young journalists, Mediosysida wants to encourage and recognize good journalistic practices in this area ”. In addition, explains “ increasingly more information professionals are joining this initiative and make a journalistic treatment with fewer prejudices towards people with HIV ”.

Isabel f. Lantigua, winner of the first edition of the prize, explains that her, for “rather than a personal recognition – that also, and done much illusion-I see this as a recognition to all those affected by HIV that they agree to tell us your story and thus contribute to put a face to the AIDS and normalize the disease ”.” “And continues, “ without them, without their testimonies, which are those who actually reach the people, the media could do little”. Isabel, editor of El Mundo, won the Mediosysida Award for his piece “ physical change, main fear of women with HIV ” last year.

Endowed with € 1,000, this award seeks to encourage young journalists about HIV that takes into account aspects such as the use of a correct language and non-discriminatory; the plurality of views and sources; the capacity for reflection and the gender approach. Competition parts can be about any topic of HIV (prevention, care and treatment, social situation, human rights, feminization of the epidemic, stigma and discrimination, labour problems, visibility of people living with HIV, international cooperation, etc.).

The second edition of this award pioneer in Spain, with the support of journalists specialized in HIV, activists, members of the University level, the National Plan on AIDS, the Ajuntament de Barcelona and private as Gilead and MSD, distinguish the best piece on HIV that has been published in a newspaper or magazine printed or digital; either by a radio or television of the Spanish State during 2010, and has addressed the public in general.

Characteristics of the prize:

-The deadline for nominations is 8/09/2011

– awarded to the best work published or broadcast between January 1 and December 31, 2010, through radio, television or print or digital press for a medium of the State Spanish.

-each contestant may submit a maximum of three pieces in any language Spanish State (Catalan, Valencian, gallego, euskera – with Spanish translation).

– in the case of pieces of collective elaboration, may participate where, as a minimum, 50% of the authors are under the age of 35 was developed when the journalistic material.

-the participants have to fill out the form located here.

-It is possible to propose pieces of other authors for the contest, prior information and permission from the author of the work. The formula to participate will be contacting Mediosysida to carry out the proposal, being the author of the piece ultimately responsible for filling out the form.

– will be granted a single prize among all the nominations, endowed with £ 1,000 and a recognition

– the jury’s decision will be made public on October 17 in the website of Mediosysida.

-the jury is composed of 1 Member of the associative field, 3 journalists of prestige and 1 member of the University Academy.

This award has the collaboration of Mediosysida is funded by: Ministry of health and Social policy – national AIDS Plan, Ajuntament of Barcelona and MSD.

what is Mediosysida.org? A media resource centre and a meeting point for online for NGOs and professionals from the information in the Spanish State. It is a project of the Red2002, created in 2002 in Barcelona during the celebration in this city of the 14th International AIDS Conference.

If you are a journalist: Mediosysida provides you faster diversity of sources of information, specialists and documentation to develop material written, visual or online on topics related to HIV/AIDS.

If you are NGOs: Mediosysida is an informative tool of your messages, activities and demands, and you also supports the creation and dissemination of notes and announcements of press between the “ mass media ” through our website and an extensive database of media in the Spanish State. It also offers workshops in communication strategies to the members of the community associations.

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips